Drägerwerk KGaA just closed at €102 after Q3 2026 earnings, with the stock roughly flat over the past week and still down double digits over the past month. On the surface that looks like a shrug. The headline is sharper. Q3 brought about €851m in revenue and basic earnings per share of €1.8, part of a trailing twelve month profit picture that now sits in single digit P/E territory versus much richer peer and industry multiples.
Short term traders are focused on a choppy chart and a soft 30 day return. Long term holders are looking at a business with improving net profit margins on a trailing view and an internal discounted cash flow value that is far above today's quote.
Love Drägerwerk KGaA's single digit P/E and improving profit picture but uneasy about the recent share price slide? Scan the 201 high quality undervalued stocks for other companies that pair compressed valuations with stronger near term momentum.
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025):€850.8m vs. €833.3m (up about 2%)
-
Net Income (Q3 2026 vs Q3 2025):€34.0m vs. €35.7m (slightly lower year on year)
-
Basic EPS (Q3 2026 vs Q2 2026):€1.80 vs. €1.57 (up about 14%)
-
Net Profit Margin (TTM Q3 2026 vs TTM Q3 2025):4.7% vs. 3.5% (improved profitability on a trailing basis)
Drägerwerk's strongest quarter is still ahead this year. Ask Charlie what Drägerwerk's Ambition 2030 roadmap could unlock .
Drägerwerk Margin Ambition Meets Mixed Q3 Reality
Optimists argue Drägerwerk KGaA is on a clear profitability march. The key ambition is simple to state and harder to hit year after year.
"The main thing that has to go right is that Medical turns consistently profitable while the company absorbs ongoing tariff, FX and logistics headwinds without derailing its ambition to add roughly 1 percentage point of EBIT margin per year toward about 10% by 2030."
Q3 and year to date numbers show partial progress. Group EBIT margin of 4.6% year to date and improved underlying EBIT point in the right direction, while Safety already sits above 11% EBIT. Medical remains loss making at €9.7m year to date, so consistent profitability there is still a milestone ahead, not one achieved.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there .
Drägerwerk Bear Case: Medical Profitability Still Off Track
The bearish worry is that Drägerwerk KGaA cannot turn Medical into a steady earnings contributor while costs keep biting.
"Management's plan to lift EBIT margin by about 1 percentage point per year through 2030 relies heavily on ongoing efficiency gains and pricing. However, the continued losses in Medical despite this focus suggest that incremental improvements may not be enough to reach around 10% EBIT margin without deeper restructuring, which would pressure earnings and cash flow."
Q3 confirms Medical is still loss making year to date at €9.7m, with Q3 EBIT only €4.5m. The group EBIT margin of 4.6% relies heavily on customs refunds, while functional costs rose faster than ideal. Execution risk around that margin ambition remains high.
Find Fresh Ideas Beyond This Chart
Drägerwerk KGaA recently reported improving trailing profitability while the share price faced pressure. The real opportunity is finding stocks that could be undervalued before the market corrects them.
-
Company 1 - 32% below our estimate - build large-scale AI compute clusters used to expand capacity for advanced model developers.
-
Company 2 - 16% below our estimate - turn recurring analytics and operational processes into bundled AI-led services that support broader client projects.
-
Company 3 - 38% below our estimate - convert long-term infrastructure and property developments into saleable assets once construction risk declines and demand stabilizes.
Three companies from the same screener. Open all 201 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DRW3.DE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
